Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells

NCT03778346 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

RRMM

Interventions

BIOLOGICAL: CAR-T therapy in Relapsed/Refractory multiple myeloma

Sponsor

The Sixth Affiliated Hospital of Wenzhou Medical University

Collaborators

[object Object]